The Brookings Institution is holding a day-long series of broadcasted panel discussions on Breakthrough Designation with the FDA. It’s running from 9:15 a.m. to 4:30 p.m. EDT.
It’ll talk about the criteria that qualifies companies in the biopharma industry for breakthrough therapy designation – a status launched in 2012 by the FDA that helps expedite approval of drugs and biologics that address unmet needs.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Here’s the discussion guide.
It largely features FDA analysts discussing Breakthrough Designations over the past two-and-a-half years, though it also brings in biopharma execs. David Kerstein, medical director of Ariad Pharmaceuticals, and Eric Rubin, a vice president at Merck, will talk on using breakthrough status in oncology.
Merck regulatory exec Robert Kowalski will speak about breakthrough designations’ implications in neurology; regulatory execs Anne-Virginie Eggimann of Bluebird Bio and Andrew Gustafson of GSK will speak on hematological disease; and Janssen Pharmaceuticals regulatory head Karin Van Baelen will discuss the topic in summary.
